Increased Risk of Intraocular Inflammation with Aflibercept Injections in Real-World Practice
Real-world use of aflibercept injections shows a higher incidence of mild intraocular inflammation compared to clinical trials, emphasizing the need for careful patient monitoring and education.
Recent research highlights that intraocular inflammation (IOI), a potential side effect of intravitreal aflibercept injections, appears to be more common in real-world clinical settings compared to controlled trials. A study published online on May 1, 2025, in JAMA Ophthalmology evaluated the occurrence of mild sterile IOI following aflibercept treatment.
The study, led by Dr. Karoline E. Binder from the Technical University of Munich, involved 41 patients receiving a total of 136 injections of 8 mg aflibercept, primarily for neovascular age-related macular degeneration and diabetic macular edema. The findings revealed that five patients developed mild sterile IOI within one to three days after injection. The incidence rate was approximately 3.7% per injection and 12% per patient. Notably, only one patient experienced inflammation after the initial dose, while the other four had prior injections.
All affected patients received localized anti-inflammatory treatments, such as topical or subconjunctival corticosteroids, with two also receiving systemic corticosteroids. Despite the inflammation, there was no impact on their visual acuity once the IOI resolved. The study authors emphasized that, although the observed IOI was mild, healthcare providers should carefully assess patient risk factors before treatment and ensure thorough patient education about potential side effects.
This research underscores the importance of vigilant monitoring during aflibercept therapy outside the controlled environment of clinical trials and highlights that mild intraocular inflammation is an important consideration in real-world practice.
Source: https://medicalxpress.com/news/2025-05-intraocular-inflammation-common-aflibercept-real.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Link Between Brain Cortex Structure and Cognitive and Psychiatric Traits
Recent research reveals causal links between the structure of the brain's cerebral cortex and mental abilities, as well as neuropsychiatric disorder risks, offering potential pathways for early diagnosis and targeted treatments.
FDA Panel Questions Kennedy's Skepticism on Antidepressants During Pregnancy
The FDA convened a panel to discuss antidepressant use during pregnancy amid skepticism from critics like Robert F. Kennedy Jr., highlighting ongoing debates about safety, efficacy, and mental health treatment for expectant mothers.
Potential Benefits of Potassium Supplements in Reducing Heart Failure Risk
Emerging research suggests that maintaining high-normal potassium levels may help lower the risk of heart failure and arrhythmias in high-risk patients. Learn about the latest findings and safe management tips.
groundbreaking trial demonstrates success of Satri-cel CAR T-cell therapy in treating solid tumors
A groundbreaking clinical trial demonstrates that Satri-cel, a targeted CAR T-cell therapy, significantly extends survival in patients with advanced gastric cancers, marking a major milestone in solid tumor immunotherapy.